Shannon Schrader

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

Kathleen Squires, Adriano Lazzarin, Jos M. Gatell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 299 citations

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

Brinda Emu, Jeffrey Fessel, Shannon Schrader et al. · New England Journal of Medicine · 2018 · 220 citations · Full text

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

David W. Haas, Carlos Zala, Shannon Schrader et al. · AIDS · 2003 · 95 citations

Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial

E DeJesus, Dennis McCarty, Charles Farthing et al. · Clinical Infectious Diseases · 2004 · 60 citations · Full text

Immunodeficiencies, Week 48, Immunology +17